Clinical evaluation for the efficacy of Muliv strong syrup in the management of Non- Alcoholic Fatty Liver disease (NAFLD).
- Conditions
- Health Condition 1: K758- Other specified inflammatory liverdiseases
- Registration Number
- CTRI/2019/12/022578
- Lead Sponsor
- Multani Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients of either sex not taking any medicine will be included in the study.
2. Individuals suffering from NAFLD with or without elevated liver enzymes or hepatomegaly will be included.
3. Patients willing to give informed consent for the study.
1. Individuals with chronic hepatitis (more than 3 months), Patients with malignant jaundice, patient with acute hepatitis (Other than infective).
2. Individuals with known hypersensitivity to ingredients of study products; individuals with immediate life threatening diseases such as preexisting cardiovascular, liver, or neoplastic diseases or who received any immunosuppressant, sedative, hypnotic or tranquilizer within 14 days prior to enrollment;
3. Individuals with any psychiatric illness which may impair the ability to provide written ICF.
4. Individuals participating in any other clinical trial.
5. Pregnant or lactating females.
6. Alcohol, smoke, and drug abusers will be excluded from study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method